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ABSTRACT 
Statins are the integral medications for the management of patients with 
acute coronary syndrome including unstable angina (UA) with multiple 
pleiotropic effects. However, the influence of statins on the coagulation 
system is controversial. Our study aimed to explore the effects of 
atorvastatin and rosuvastatin in high doses on some coagulation parameters 
(prothrombin pool (PP) and soluble fibrin-monomer complexes (SFMC) 
concentration) after a 7-days follow-up period in patients with UA. We 
recruited 50 patients aged 55 to 70 years with progressive UA. Standard 
therapy according to ESC guidelines 2020 was recommended for all 
patients. Before treatment onset, they were divided into 2 groups: group A 
– 26 patients were prescribed atorvastatin, group R – 24 patients with 
rosuvastatin treatment. The blood samples to analyze the concentration of 
PP and SFMC were collected twice – before the treatment onset and 7 days 
after. We revealed significant decrease in PP concentration (p=0,02) and 
increase in SFMC concentration (p=0,01) in group A patients while there 
were no significant changes of investigated parameters (p=0,94, p=0,57 
respectively) in group R. Additionally, we have noted significant negative 
correlation between baseline PP concentration and direction of PP changes 
(r=-0,803, p<0,001) as well as PP changes direction and SFMC 
concentration after treatment (r=-0,655, p<0,001). Thus, we may consider 
that atorvastatin and rosuvastatin are characterized by different influences 
on coagulation in patients with progressive UA with standard basic 
treatment. The rebound coagulation system activation after anticoagulant 
discontinuation is more pronounced in UA patients against a background 
of atorvastatin treatment in comparison with rosuvastatin. 
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Introduction. Statins (3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors) are considered a cornerstone in prevention and treatment of atherosclerosis and its 
complications [1, 2], as it was shown that this group of medicines reduces the risk of major vascular 
events [3] as well as cardiovascular and all-cause mortality [4].  
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While the enormous targeted investigations were performed to analyze the data regarding the 
direct pharmacological hypolipidemic mechanism of statins [5], the plethora of statins’ pleiotropic 
effects was revealed [6]. Most of them are explained by the anti-inflammatory properties of statins [7]. 
Thus, statins adjust two main pathogenetic mechanisms of coronary artery disease progression, 
particularly dyslipoproteinemia and inflammation. It was found that even short-term treatment with 
statins influence on coronary heart disease, which is of high importance regarding the management of 
patients with acute coronary syndrome [8]  
Far less attention is paid to the influence of statins onto the hemostasis, though the latter 
imbalance occupies a fitting first place especially in case of coronary artery disease destabilization, 
when atherothrombosis occurs [2].  
Traditionally, acute cardiovascular events are reckoned to be connected tightly with the 
formation of platelet-rich thrombi. But the insufficient effect of even double antiplatelet therapy and 
finally results of autopsy findings with fibrin-rich thrombi that cause myocardial infarction suggest the 
underestimated role of the coagulation with thrombin as the central enzyme [9] and its precursor 
prothrombin. Consequently, it stands to reason that anticoagulants are mandatory medicines for the 
management of patients with acute coronary syndrome [2]. Soluble fibrin monomer complex (SFMC) 
which is famous for its diagnostic potential in patients with myocardial infarction and unstable angina 
(UA) [10] is one of the coagulation cascade intermediate products with further fibrin polymer 
formation as the direct way to thrombosis occurrence [11]. 
Ancillary effects of statins on the coagulation system were described in several reviews but 
with a note about rather controversial results of studies. There is some data about the influence of 
statins on thrombin and fibrin [12, 13].  
Thus, the main target of our study was to investigate whether the difference between statins 
regarding changes in blood plasma coagulability exists. Among all types of statin, it was chosen 
atorvastatin and rosuvastatin as the most widely used representatives of this group which vary in their 
lipophilicity, elimination half-life, potency, and the mevalonic acid pathway influence [14]. For this 
purpose, we have analyzed 2 parameters: SFMC and prothrombin pool (PP) which reflects the 
concentration of all molecules with epitopes of prothrombin origin [15]. A 7-days follow-up period 
(36 hours after anticoagulant withdrawal) was of high interest for us as just at this time the risk of 
thrombotic events increases.  
Materials and Methods. In our prospective observational study, we recruited 50 patients aged 
between 55 and 70 years old (19 females (38%)) which were hospitalized to the cardiology department 
with an established diagnosis of progressive unstable angina. Also, we included only those patients who 
had not been taking statins for at least 3 months (mainly, because of low compliance with treatment). 
The protocol of the study was approved by the Research Ethics Committee of the Bogomolets 
National Medical University. The patients gave written consent to participate after the explanation of 
the survey design. 
All patients received conservative standardized treatment according to the current ESC 
Clinical Practice Guidelines [2], particularly anticoagulant (enoxaparin 1 mg/kg twice daily 3 days, 0,5 
mg/kg twice daily 2 days subcutaneously), acetylsalicylic acid (ASA) 75 mg once daily, clopidogrel 
75 mg once daily, bisoprolol in dosage depending on heart rate (HR) and blood pressure (BP) once 
daily, angiotensin-converting enzyme inhibitor (ACEi) (enalapril/ramipril/perindopril in individual 
dosage), nitrates in infusion once daily and 20 mg in tablets twice daily, pantoprazole 20 mg once 
daily. But depending on statin therapy which was prescribed the patients we formed 2 groups. The 
patients of group A have been treated with atorvastatin 60 mg per day, while the patients of group R 
were recommended rosuvastatin 20 mg per day. Such a dosage is believed to be equivalent to these 
medicines [16]. The follow-up period was 7 days. 
The exclusion criteria were conditions with a possible thrombophilic state such as heart 
defects, persistent atrial fibrillation / atrial flutter, cardiomyopathies, non-ischemic myocardial 
injuries, heart failure IIB-III stage, endocrinological disorders, active infection, chronic diseases in the 
period of exacerbation, blood diseases including coagulopathies, anemia of II-III stage, glomerular 
filtration rate less than 60 ml/min./1,73 m2, hepatic dysfunction, malignancy, traumas, and bleedings 
within 6 months before this study, myocardial infarction or stroke within 1 year before this survey. 
Immediately after admission the patients passed the general clinical examination with 
anamnesis gathering, ECG at rest registration, qualitative troponin I test.  
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If according to the preliminary information the patient met inclusion criteria we collected blood 
samples for hemostatic parameters under investigation (PP, SFMC) before initiation of treatment. We 
controlled above mentioned hemostatic parameter after 7 days of treatment (36 hours after enoxaparin 
discontinuation). Blood samples were taken by phlebotomy in sodium citrate, centrifugated, aliquoted, 
and frozen until use. We determined SFMCs concentration by colorimetric orthophenanthroline method. 
We used ELISA immune assays with primary and secondary antibodies following the manufacturer’s 
instructions (Santa Crus Biotechnology, CA, USA) to evaluate PP concentration. 
Also, we performed echocardiography as well as a basic routine blood analysis set (hepatic 
and renal panel, complete blood count, lipidogram) and hs-Troponin I test.  
We used SPSS (version 22, IBM Corp, USA) for data analysis. Test for normality was 
provided with the Shapiro Wilk test. We presented numerical data as the median with interquartile 
range (Me(IQR)), while nominal variables were reported in absolute values (percentage) and 
compared by using the chi-squared test (χ2). We used the Mann-Whitney (U) test for unpaired samples 
and the Wilcoxon test (W) for paired samples to weigh the differences between numerical variables. 
The correlation between variables was examined with the use of Pearson or Spearman correlation 
depending on the type of variables. P-value <0,05 was considered statistically significant. 
Results. In our survey we included 50 patients (age 66,0 (60,0-67,0) years, 19 females 
(38,0%)) with progressive UA. In general, both groups are comparable, and some peculiarities of the 
investigated population are reported in further tables. 
Baseline characteristics of patients are presented in table 1. There was no significant 
difference between groups including preliminary treatment. The latter is rather important while taking 
into account multiple indirect influences of medicines onto coagulation. Relatively low compliance 
with the treatment should be mentioned in recruited patients. 
Table 1. Baseline characteristics of patients 
Parameter Group A Group R p 
Age, years 63,0(60,0-67,3) 66,0 (64,0-67,0) 0,39 
Females, n (%) 8 (42,1) 11 (57,9) 0,27 
BMI, kg/m2,  30,6 (27,2-32,7) 28,3 (26,7-30,0) 0,06 
Preliminary treatment 
RAASi, n (%) 18 (69,2) 19 (79,2) 0,07 
Diuretic, n (%) 6 (23,1) 7 (29,2) 0,75 
CCB, n (%) 2 (7,7) 2 (8,3) 0,89 
β-blocker, n (%) 13 (50,0) 14 (58,3) 0,14 
ASA, n (%) 8 (30,8) 11 (45,8) 0,38 
Nitrate, n (%) 2 (7,7) 5 (20,8) 0,23 
BMI – body mass index; RAASi – inhibitor of renin angiotensin aldosterone system; 
CCB – calcium channel blocker, ASA – acetylsalicylic acid 
Table 2 represents 3 main groups of criteria according to which the diagnosis was established, 
particularly clinical features, biochemical marker (hs-cTn) and ECG changes while admission. Though 
in general two groups are consistent, hs-cTn concentration tends to be higher in group R. 
Table 2. Diagnostic criteria of unstable angina among the groups 
Parameter Group A Group R p 
Complaints while admission 
Typical pain, n (%) 16 (61,5) 17 (70,8) 0,12 
Atypical pain, n (%) 6 (23,0) 6 (25,0) 0,72 
Dyspnoe (equivalent), n (%) 2 (7,7) 1 (4,2) 0,24 
    
hs-cTn, pg/ml 21,95 (17,72-28,62) 27,00 (22,25-30,95) 0,08 
    
HR, beats/min. 76,0 (70,0-83,0) 72,0 (70,0-78,0) 0,17 
ST-segment depression, n (%) 16 (61,5) 20 (83,3) 0,09 
T wave variability, n (%) 15 (57,7) 17 (70,8) 0,38 
New-onset LBBB, n (%) 2 (7,7) 0 0,49 
hs-cTn – high sensitive cardiac troponin; HR – heart rate; LBBB – left bundle branch block 
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Chest pain was the prevailing complaint in observed patients (90,0%). 33 patients (66%) 
suffered from typical retrosternal pain which was provoked by minimal physical exertion or even at 
rest, others described the discomfort in cardiac region (6, (12,0%)), in scapular region (6, (12,0%)), 
dyspnoe as the only possible equivalent of pain (3 (6%)) or just general fatigue which occurs suddenly 
(2 (4%)). Other additional complaints included dyspnoe (70,4%), palpitation (59,8%), headache 
(40,5%), dizziness (40,8%). In general, regarding complaints the groups were comparable.  
The results of basic biochemical tests, echocardiography and BP while admission are 
demonstrated in table 3. Lipidogram parameters of both groups patients were above recommended 
targeted levels for high-risk patients while other biochemical characteristics were within normal ranges. 
Table 3. General baseline laboratory and instrumental characteristics 
Parameter Group A Group R p 
TC, mM/L 6,03 (4,85-6,82) 4,99 (4,57-6,61) 0,16 
LDL-C, mM/L 3,45 (2,19-4,66) 3,02 (2,62-3,35) 0,11 
HDL-C, mM/L 1,20 (1,07-1,67) 1,42 (0,97-1,84) 0,64 
TGs, mM/L 2,27 (1,60-2,83) 1,97 (1,26-2,27) 0,08 
    
ALT, IU/L 0,75 (0,65-0,92) 0,75 (0,65-0,83) 0,19 
AST, IU/L 0,60 (0,50-0,70) 0,55 (0,50-0,64) 0,45 
GFR, mL/min/1,73 m2 60,0 (47,0-81,0) 59,5 (45,0-71,0) 0,55 
Glucose, mM/L 4,8 (3,9-5,8) 5,0 (4,3-5,6) 0,38 
    
WBC, x109/L 7,8 (6,8-8,2) 7,8 (5,8-9,6) 0,53 
RBC, x1012/L 5,0 (4,5-5,3) 4,8 (4,3-5,1) 0,13 
Hb, g/L 145,0 (132,0-148,0) 138,0 (133,0-146,0) 0,17 
Platelets, x109/L 256,0 (201,0-292,0) 243,5 (170,0-384,0) 0,94 
    
EDV, mL 118,0 (109,0-129,0) 113,0 (100,0-121,0) 0,34 
ESV, mL 43,2 (33,7-68,0) 42,0 (39,0-63,0) 0,54 
IVS, mm 1,21 (1,11-1,40) 1,21 (1,10-1,24) 0,32 
EF, % 55,5 (50,0-61,0) 61,0 (55,2-63,0) 0,14 
    
sBP, mmHg 150,0 (140,0-160,0) 147,5 (120,0-160,0) 0,91 
dBP, mmHg 90,0 (82,0-92,5) 86,0 (80,0-93,0) 0,52 
TC – total cholesterol; LDL-C – low-density lipoprotein cholesterol; HDL-C – high-density 
lipoprotein cholesterol; TGs – triglycerides; ALT – alanine transaminase; AST – aspartate 
transaminase; GFR – glomerular filtration rate; WBC – white blood cells; RBC – red blood cells; 
Hb – hemoglobin; EDV – end-diastolic volume; ESV – end-systolic volume; IVS – interventricular 
septum; EF- ejection fraction; sBP – systolic blood pressure; dBP – diastolic blood pressure 
The investigated patients were characterized by hypertensive left ventricular hypertrophy with 
preserved ejection fraction. Also, while admission the normal blood pressure was registered only in 6 
patients (12%).  
To sum up all above-mentioned the groups were comparable by main characteristics. 
The dynamic changes of investigated hemostatic parameters are shown in table 4. 
Table 4. The concentration of prothrombin pool (PP) and soluble fibrin-monomer complexes 
(SFMC) before the treatment and after 7 days follow-up period 
Variable Group A 
n=26 
Group R 
n=24 
p§ p# 
Before  After p* Before After p* 
PP,  
rel.units/mL 
0,163 
(0,158-0,175) 
0,158  
(0,151-0,164) 
0,02 0,166  
(0,158-0,178) 
0,168  
(0,157-0,174) 
0,94 0,62 0,001 
SFMC, 
μg/mL 
15,5 
(10,0-17,0) 
18,0  
(15,8-21,0) 
0,01 19,0  
(15,0-22,5) 
18,5  
(16,0-22,7) 
0,57 0,01 0,31 
PP – prothrombin pool; SFMC – soluble fibrin monomer complexes; before – at baseline; after – 
after 7-days follow-up period; * - paired-test (W) in each group as compared to baseline; § - p of 
intergroup comparison at baseline (unpaired U-test); # - p of intergroup comparison after follow-up 
period (unpaired U-test) 
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Before treatment PP concentration did not significantly differ between groups in contrast to 
SFMC concentration which was higher in group R. The same baseline trend was regarding hs-cTn 
concentration. However, after treatment, we registered the opposite relationship between the 
investigated parameters of groups. Thus, while the SFMC’s concentration between groups was 
compatible, the PP concentration in group R was significantly higher than in group A. At the same 
time there were no significant changes of PP (-0,59 (-2,46-2,90)%) and SFMCs (-0,36 (-19,6-8,6)%) 
concentration in group R unlike group A in which we noted significant decrease in PP concentration 
by 4,9% (-4,9( -10,8-1,84)%) and increase in SFMC concentration by 10,8 (2,7-21,3)%. 
We have noticed intragroup differences in direction of changes that are presented in Table 5. 
A percentage of SFMC changes with the upward direction was significantly higher in group A. 
Meanwhile, no significant difference was noted in group R, though the downward trend of PP 
concentration in group A was in 65,4% of patients. 
Table 5. Peculiarities of coagulation parameters changes among 
Variable Group A Group R 
p Decrease, 
n (% of group) 
Increase, 
n (% of group) 
Decrease, 
n (% of group) 
Increase, 
n (% of group) 
PP,  
rel.units/mL 
17 (65,4) 9 (34,6) 13 (54,2) 11 (45,8) 0,42 
SFMC, 
μg/mL 
5 (19,2) 21 (80,8) 12 (50,0) 12 (50,0) 0,02 
Finally, we have checked correlations between investigated parameters in observed groups. In 
terms of group A it was found strong negative correlation between PP concentration before treatment 
and direction of PP changes (r=-0,803, p<0,001), direct correlation of mild strength between PP and 
SFMC concentrations before treatment (r=0,626, p=0,001) as well as concentrations of PP before 
treatment and SFMC after (r=0,447, p=0,02). Also, negative relations of mild strength were noticed 
between PP changes direction and SFMC before treatment (r=-0,530, p=0,005) as well as after 
(r=-0,655, p<0,001). 
In the group R we have noticed direct correlation between PP concentration before and after 
treatment (r=0,912, p<0,001) as well as SFMC concentration before and after (r=0,746, p<0,001). 
Though there were no significant relations between PP and SFMC concentrations before and after 
treatment, we have noted indirect relations between directions of PP and SFMC concentration changes 
(r=-0,585, p=0,003). 
Discussion. The results of our study confirm several statements regarding statins’ influence on 
organism and drug-drug relations, however, with some practical supplement.  
Currently, there is no doubt in the short-term positive effects of high-dose statin therapy on the 
course of ACS. Zhi-Jian Liu et al. reported a significant decrease in high sensitive C reactive protein 
and malonaldehyde as markers of inflammation and oxidative stress respectively in patients with acute 
myocardial infarction and successful primary percutaneous coronary intervention received high-dose 
atorvastatin therapy in comparison with moderate after only 7 days follow-up period [17].  
However, as far as we know almost no data is regarding the effects of statins on blood plasma 
coagulability after a short follow-up period as most investigators have described the data regarding a 
more prolonged period of statins’ treatment. In general, it was mentioned that a decrease in thrombin 
generation is highly suggestive [18], especially in patients with hypercholesterolemia [19]. Tonu S. et 
al. registered a significant increase in prothrombin time after 8 weeks of treatment with atorvastatin 
and rosuvastatin in low doses [20]. Fenton et al. found out that simvastatin downregulated thrombin 
generation as prothrombin fragments F1+F2 in the blood plasma of type 2 diabetes patients were 
lowering after the treatment period [21]. On the other hand, it was reported no influence of statin on 
thrombin generation in patients with ACS [22]. 
The data regarding statins’ influence on fibrinogen concentration as the source of SFMC are 
not less controversial. However, predominantly it was shown the impaired fibrinogen cleavage, 
decrease the amount of fibrinopertides after statin treatment, changes of fibrin clot characteristics [12]. 
In our study, we have registered a significant decrease in PP concentration and an increase in 
SFMC concentration in patients with progressive unstable angina after 7 days atorvastatin course 
unlike in patients after the rosuvastatin course no significant changes of both parameters were noted. 
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At first glance, a decrease in PP concentration is considered to be a good prognostic sign. However, an 
increase in SFMC concentration is supposed to be a marker of increased risk of thrombotic 
complications. We presume such condition may be connected with the “exhaustion” of PP after 
intensified coagulation with the active formation of SFMC. Such a decrease in coagulation potency 
may be in consequence of rebound thrombin generation after anticoagulant discontinuation [23]. 
The negative correlation between PP concentration before treatment and direction of PP 
changes as well as the positive relation between the concentration of PP before and SFMC after 
treatment come in support of our assumption.  
In terms of rosuvastatin, a few peculiarities should be defined. Some pleiotropic effects of 
statins are supposed to be connected with the nonsterol isoprenoid pathway. It was shown the reduced 
expression of ubiquinone, dolichol synthesis, and protein prenylation pathway in recombinant yeast 
strain with human HMGR by atorvastatin whereas rosuvastatin caused diverse effects (expression of 
BTS1, COQ3, RER2 and downregulation of COQ2, CAT5, SEC59) [14]. Such finding direct to the 
possibility of intragroup distinctions between accessory effects of statins.  
Another point that should be mentioned is drug interactions between clopidogrel as medicine 
for double antiplatelet therapy and statins. While rosuvastatin is transformed by CYP2C9, clopidogrel 
and atorvastatin are metabolized by CYP3A4 isoenzyme of cytochrome P450 (CYP) [24]. The latter 
peculiarity of atorvastatin may cause an increase in major adverse thrombotic events [25]. The 
observed trend in the rosuvastatin group may be connected with either the above-mentioned facts.  
We are inclined to qualify the absence of dynamic in group R after enoxaparin withdrawal as a 
better trend than a decrease in PP along with an increase in SFMC concentration. 
Conclusions. 
1. Statins are characterized by different influences on coagulation in patients with UA. 
2. The rebound thrombin generation after enoxaparin discontinuation is less marked in UA 
patients against a background of rosuvastatin treatment in comparison with atorvastatin.  
3. Rosuvastatin should be preferable to atorvastatin for patients with unstable angina if there 
was no previous statin treatment. 
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